Article
Anxiety and dysautonomia symptoms in patients with a NaV1.7 mutation and the potential benefits of low-dose short-acting guanfacine.
Clinical autonomic research : official journal of the Clinical Autonomic Research Society - 1 Feb 2024
de Cássia Collaço Rita, Lammens Maxime, Blevins Carley, Rodgers Kristen, Gurau Andrei, Yamauchi Suguru, Kim Christine, Forrester Jeannine, Liu Edward, Ha Jinny, Mei Yuping, Boehm Corrine, Wohler Elizabeth, Sobreira Nara, Rowe Peter C, Valle David, Brock Malcolm V, Bosmans Frank
Abstract excerpt
PURPOSE: Guanfacine is an α2A-adrenergic receptor agonist, FDA-approved to treat attention-deficit hyperactivity disorder and high blood pressure, typically as an extended-release formulation up to 7 mg/day. In our dysautonomia clinic, we observed that off-label use of short-acting guanfacine at 1 mg/day facilitated symptom relief in two families with multiple members presenting with severe generalized anxiety....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.